News

Malaysia is the 20th country to approve the company’s Phase III trial, which has now enrolled more than 350 patients with advanced primary, not yet treated, head and

Currently, Questcor operates as the autoimmune and rare diseases business of Mallinckrodt Pharmaceuticals. In Canada, Synacthen Depot is approved for therapeutic use in patients diagnosed with many difficult-to-treat

Recently, the company has also leased a clinical manufacturing facility in Santa Monica, California. The expansion of the manufacturing capabilities will help the firm to support the development

The deal will see the two companies supply panels of antibodies to develop bispecific antibody products using Genmab’s DuoBody platform technology. If a product candidate is developed for

The research alliance will focus on GI sensory and motor mechanisms underlying functional bowel disorders and GI motility disorders. The University’s Neurogastroenterology Group aims to understand the neuromuscular

As part of the deal, J-Network has an exclusive one-year renewable license for the marketing and sales of TRGM’s proprietary product, designed to improve sleep and immune function,

The company focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nanoparticulates, drug/device combination products, solid solutions

Adcetris is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma (sALCL). The Phase III trial of Adcetris

According to the company, the initial indications for AMPLEX and PREFIX to be investigated are fusion in foot/ankle and lumbar spine surgical procedures, respectively. The two products are